Accelerated Approval Pathways: Speed Without the Stumbles
Lakshmi, Editorial Team, Pharma Focus Europe
Europe's expedited routes — conditional marketing authorisation, approval under exceptional circumstances, and the PRIME scheme — let promising therapies reach patients years early by relying on early or surrogate evidence, with confirmation to follow. But unfulfilled specific obligations, contentious renewals, and the tension between EMA science and national reimbursement have exposed the framework's fault lines. This article examines the legal and regulatory hazards of Europe's accelerated pathways and the disciplines that let leaders move fast without stumbling.
Introduction:
When a therapy for a devastating disease sits finished in a laboratory while patients wait, the arithmetic of a traditional approval timeline becomes unbearable. Europe's accelerated approval pathways were built precisely for this moment — to compress the distance between a promising molecule and a prescription pad. Yet speed has always carried a shadow. The same mechanisms that deliver breakthrough medicines to desperate patients years ahead of schedule can, when mishandled, usher through therapies whose benefit never materialises. For senior leaders navigating European regulatory strategy, the challenge is no longer whether to pursue expedited routes, but how to move fast without stumbling into the reputational, legal, and financial hazards that increasingly line the road.
The European Toolkit for Speed
Unlike some markets that lean on a single expedited mechanism, the European Union offers a layered set of instruments, each resting on a distinct legal footing. Conditional marketing authorisation permits the European Medicines Agency to recommend approval on the basis of less complete data than normally required, provided the benefit-risk balance is positive, the applicant is likely to supply comprehensive data later, an unmet medical need is addressed, and the benefit to public health of immediate availability outweighs the risk inherent in still-missing evidence. The authorisation is granted for one year and renewed annually until the outstanding obligations are met, at which point it can convert to a standard authorisation.
Approval under exceptional circumstances serves a different purpose. It applies where comprehensive data can never realistically be generated — because the condition is so rare that a full dataset is unattainable, or because collecting it would be contrary to accepted ethical principles. Here the sponsor is not expected to complete the evidence base later; instead, the therapy remains under continuous review with specific obligations attached, typically in perpetuity.
Layered above these authorisation routes sits PRIME — Priority Medicines — a scheme designed not to lower the evidentiary bar but to accelerate the journey toward it through enhanced regulatory support, early dialogue, and the prospect of accelerated assessment for medicines targeting unmet needs. Together these instruments form a spectrum, from full support during development to conditional and exceptional authorisation at the point of market entry.
The Bargain at the Heart of Acceleration
Across these routes runs a common bargain. A regulator agrees to grant marketing authorisation based on early evidence — often a surrogate endpoint such as a laboratory measurement, imaging result, or biomarker reasonably likely to predict clinical benefit — rather than waiting for direct evidence that patients live longer or better. In exchange, the sponsor accepts specific obligations: confirmatory studies, registries, or post-authorisation efficacy and safety monitoring that verify real-world benefit after the medicine is already available.
It is a bargain made in good faith on both sides, and for decades it has done remarkable good. Therapies for cancer, rare genetic disorders, and infectious diseases have reached European patients years earlier than conventional evidence standards would have permitted. The framework acknowledges a hard truth: for someone with an aggressive, untreatable condition, the theoretical risk of an unproven drug can be smaller than the certain risk of no drug at all.
The difficulty is that early evidence is a promise, not a guarantee. A tumour may shrink without the patient living longer. A biomarker may improve while the disease quietly progresses along another axis. When the confirmatory evidence eventually arrives and contradicts the surrogate, the regulator, the sponsor, and the patient are all left holding a product that reached the market on a prediction that proved false.
When the Obligations Go Unfulfilled
The most persistent criticism of accelerated approval is not that surrogate endpoints occasionally mislead — that is an accepted scientific risk — but that the confirmatory follow-through has too often been slow, incomplete, or subject to repeated extension. For a conditional marketing authorisation, the entire logic depends on the sponsor supplying the comprehensive data on which the specific obligations rest. When those studies slip year after year while the annual renewal is nonetheless granted, the pathway begins to lose the discipline that justified it.
This is the stumble that has drawn the fiercest scrutiny across Europe. A pathway premised on later verification loses its integrity the moment that loop goes unclosed. The patient told a therapy was reasonably likely to help deserves eventually to know whether it actually did. Payers financing these treatments deserve to know whether they are funding benefit or merely hope. And the public trust in the regulatory system — the currency that makes expedited approval acceptable in the first place — erodes each time a specific obligation is quietly deferred.
The EMA has responded by tightening its expectations. Specific obligations are increasingly framed with concrete milestones and timelines rather than open-ended commitments, and the annual renewal has become a genuine checkpoint at which progress is examined rather than assumed. The message to sponsors is unambiguous: the confirmatory study is not a formality to be postponed indefinitely, but the load-bearing element of the entire arrangement.
The Renewal and Withdrawal Question
Removing an authorised therapy is among the most fraught actions a regulator can take, and it sits at the legal fault line of the accelerated framework. When confirmatory data fail to demonstrate the promised benefit, or when the sponsor fails to fulfil its specific obligations, the logically clean answer is to decline renewal or vary the authorisation. In practice, the process is anything but clean.
Patients who believe a drug is helping them — and their advocates — often resist withdrawal fiercely, even when the aggregate evidence shows no benefit. Physicians who have prescribed a therapy develop clinical conviction that can outlast the data. Sponsors, facing the loss of a revenue stream and the admission that a flagship product did not deliver, have every incentive to contest an adverse decision, including through appeal to the European courts. The result can be prolonged proceedings during which a therapy of unproven benefit remains available across member states.
For company leadership, this creates a delicate strategic calculus. Contesting a non-renewal may preserve short-term revenue, but it invites lasting damage to credibility with the EMA, national competent authorities, and payers — relationships that outlast any single product. The more defensible posture is to build the confirmatory evidence base with genuine rigour from the outset, so that the renewal question, if it turns adverse, is answered by data the company itself trusts rather than by a contest of wills with the regulator.
The EMA–Reimbursement Gap
A distinctively European stumble arises from the structural separation between authorisation and access. The EMA's centralised procedure grants a marketing authorisation valid across the entire Union, but it says nothing about whether any given health system will pay for the medicine. Reimbursement remains a national — and often regional — competence, decided by health technology assessment bodies applying their own evidentiary thresholds.
This creates a familiar and frustrating asymmetry. A therapy may secure conditional marketing authorisation on early evidence the EMA considers sufficient for approval, only to be judged inadequate by national HTA bodies demanding harder outcomes data before they will fund it. A medicine can thus be legally available yet practically inaccessible across large parts of Europe, its accelerated approval delivering a licence but not a patient. The new EU-level joint clinical assessment framework aims to bring greater coordination to the clinical evidence review that underpins these national decisions, but pricing and reimbursement judgements themselves remain firmly in national hands.
For leaders, the lesson is that an accelerated authorisation is a beginning, not an endpoint. A development programme designed only to clear the EMA's benefit-risk bar, without an eye to what payers across member states will demand, risks a launch that is regulatory triumph and commercial disappointment in equal measure. Aligning the confirmatory evidence with the outcomes payers actually value is what turns an approval into access.
Real-World Evidence: Promise and Peril
The rise of real-world evidence — data drawn from electronic health records, registries, and patient-reported outcomes — has introduced a powerful new instrument into Europe's accelerated toolkit. In principle, real-world data can help fulfil specific obligations faster and more affordably than a traditional randomised trial, particularly for rare diseases where assembling a large controlled study is impractical or ethically vexed. Registry-based evidence has become a common feature of authorisations granted under exceptional circumstances.
The peril is that real-world evidence is only as trustworthy as its design and sources. Observational data carries confounders that randomisation is specifically built to neutralise; a therapy may appear effective in a registry simply because healthier patients received it. European regulators are increasingly receptive to real-world evidence — the EMA's data infrastructure initiatives reflect that openness — but their receptiveness is conditional on methodological rigour: prespecified analyses, transparent data provenance, and honest accounting of limitations. Sponsors who reach for real-world evidence as a shortcut around rigorous design, rather than a complement to it, invite exactly the kind of stumble that discredits the broader enterprise.
Building Speed That Holds
The organisations that navigate European accelerated approval well share disciplines that senior leaders would do well to institutionalise. The first is treating specific obligations as a first-class element of the development plan, funded and initiated with the same seriousness as the pivotal study that won approval — not as an afterthought to be renegotiated at renewal. Confirmatory studies designed, enrolled, and resourced early are the single most powerful safeguard against the erosion that undermines a conditional authorisation.
The second discipline is early, candid regulatory engagement. Surrogate endpoints, confirmatory designs, and post-authorisation commitments are far better settled through EMA scientific advice, and where eligible through PRIME's enhanced dialogue, than discovered as points of contention afterward. A regulator who has been consulted throughout is a partner in the acceleration; one presented with a fait accompli is an obstacle.
The third is intellectual honesty about the surrogate itself. Not every biomarker deserves the confidence placed in it. Leaders who invite rigorous internal challenge to the assumption that their chosen surrogate truly predicts benefit — rather than suppressing that challenge in the interest of speed — are least likely to be blindsided when confirmatory data arrive.
The fourth is transparency with patients and payers. When a therapy is authorised on the basis that it is reasonably likely to help, saying so plainly — rather than marketing it as though the benefit were established — preserves trust and reduces the reputational whiplash if confirmation falters, and it prepares the ground for the HTA conversations that determine access.
The Deeper Stakes
It is tempting to frame accelerated approval purely as a regulatory and legal problem to be managed. But underneath the frameworks and the specific obligations lies a moral proposition that every leader in the field should hold clearly in view. The pathway exists because there are patients for whom waiting is not a neutral act — for whom the traditional timeline is itself a harm. Every tightening of confirmatory requirements, every renewal review, every methodological debate about surrogates is, in the end, an effort to keep faith with those patients: to ensure that the speed they are offered is real benefit and not merely its appearance.
The stumbles that have marred accelerated approval — the specific obligations that slipped year after year, the non-renewals that dragged through the courts, the surrogates that flattered to deceive, the licences that never became access — were not failures of speed. They were failures of follow-through. Speed itself is not the enemy; unaccountable speed is. The framework works when acceleration and verification move together, each disciplining the other, so that a fast authorisation is a down payment on a promise the sponsor fully intends to keep.
For the executives shaping tomorrow's European development strategies, the mandate is therefore not to choose between velocity and rigour, but to fuse them. The competitive advantage in the years ahead will belong not to the companies that reach the market fastest, but to those that reach it fast and stay there — their conditional authorisations converted, their surrogates vindicated, their patients genuinely better off. That is speed without the stumbles: not a slower journey, but a surer one.
Lakshmi is a science writer with a foundation in the laboratory. She earned her master's in biotechnology and trained through research internships at ICGEB (JNU) and DIPAS, DRDO, with her work appearing in the Egyptian Journal of Veterinary Sciences. Now APCRM-certified and part of the editorial team at Pharma Focus America and Pharma Focus Europe, she reports on pharmaceutical technology, research, and innovation — giving complex science a clear and confident voice for industry leaders.
